Leukemia Clinical Trials

Find Leukemia Clinical Trials Near You

Standardised Quantification of Invariant NKT Cells Using DryTube Technology and Flow Cytometry in Patients Who Have Undergone Allogeneic Haematopoietic Stem Cell Transplantation.

Status: Recruiting
Intervention Type: Diagnostic test
Study Type: Observational
SUMMARY

The transplantation of allogeneic haematopoietic stem cells (HSCs) can lead to serious complications after transplantation, such as graft-versus-host disease (GvHD), infections and relapse due to immunosuppression. Invariant NKT cells (iNKT cells) play a pivotal role in modulating the immune response and have been demonstrated to be instrumental in the pathogenesis of GvHD, cytomegalovirus (CMV) infection, and relapse. Their levels are associated with the development of these complications. This multicentre study aims to test the feasibility of standardising iNKT cell monitoring and to investigate the association between iNKT cell levels and post-transplant complications.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 70
Healthy Volunteers: f
View:

• Diagnosis: AML (exlusion of secondary disease)

• Disease status at time of HSCT: complete remission

• Karnofsky performance status: ≥80%

• Source of HSC: PBSC

Contact Information
Primary
Monika Holubová, MSc.
holubovam@fnplzen.cz
+420 377 103 991
Backup
Lenka Lukášová, MD, MSc.
LUKASOVALE@fnplzen.cz
+420 377 103 871
Time Frame
Start Date: 2026-08-01
Estimated Completion Date: 2029-01-31
Participants
Target number of participants: 75
Treatments
HSCT patients
Patients who have undergone allogeneic hematopoietic cell transplantation and have been diagnosed with acute myeloid leukemia.
Sponsors
Leads: University Hospital Pilsen

This content was sourced from clinicaltrials.gov